* Transgene presents new data with TG1050, an immunotherapy
being developed to treat chronic hepatitis B, at the
international liver congress 2015
* Data presented demonstrate antiviral potential of TG1050
in a persistent hepatitis B virus (HBV) in vivo model
* TG1050 was shown to significantly reduce circulating HBV
DNA, to reduce circulating HBV surface antigen, and to trigger
seroconversion to HBsAg (i.e., to develop anti-HBsAg antibodies)
Source: Reuters
Labels: EASL 2015, TG1050, Transgene